Castle Creek acquisition of Fibrocell : Castle Creek Pharmaceutical Holdings (CCP Holdings) has agreed to acquire Fibrocell Science, a cell and gene therapy company engaged in developing autologous cell-based therapies for skin and connective tissue disorders.
Financial terms of the deal were not disclosed, as per the latest pharma industry news.
CCP Holdings is a holding company that holds stakes and makes investments in companies across the orphan dermatology space. Included in these is Castle Creek Pharmaceuticals, a biopharma company that is focused on developing therapies for patients having rare, serious or debilitating dermatologic conditions.
Through Castle Creek Pharmaceuticals, the gene therapy platform of Fibrocell is expected to be advanced into more areas of high, unmet need with the possibility to develop multiple, promising new therapies, said CCP Holdings.
Commenting on Castle Creek acquisition of Fibrocell, Greg Wujek – CEO of Castle Creek, said: “Our current licensing and development collaboration with Fibrocell, which began in April 2019, has cemented a shared focus on delivering the first approved therapies for families who are impacted by rare dermatologic conditions like epidermolysis bullosa (EB), a chronic, painful and debilitating disease that leads to severe blistering starting early in life and can only be treated with palliative care including extensive bandaging.
“As one company, we will be in a strong position to push forward initially with two late-stage clinical development programs targeting different types of EB with investigational gene and topical therapies, and one potential therapy for scleroderma.”
Epidermolysis bullosa, which is a rare genetic disorder, causes extremely weak skin leading to mild to severe blistering, skin erosion and peeling of the epidermis layers whenever there is a minor injury. Currently, there are no approved treatment options in the US for any form of epidermolysis bullosa.
Both Castle Creek and Fibrocell have advanced investigational therapies for the treatment of multiple forms of epidermolysis bullosa into late-stage clinical research.
FCX-007 – the lead gene therapy candidate of Fibrocell is being studied in a phase 3 trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Additionally, Fibrocell is assessing another investigational gene therapy FCX-013 in moderate to severe localized scleroderma in a phase 1/2 trial.
Castle Creek is expected to continue Fibrocell’s ongoing research and development. The company will also continue phase 2b development of CCP-020 for epidermolysis bullosa simplex (EBS) and other types of epidermolysis bullosa.
Dr. Mary Spellman – Chief Medical Officer and Senior Vice President of Castle Creek Research & Development, commenting on Castle Creek acquisition of Fibrocell, said: “Fibrocell’s unique and innovative gene therapy platform provides us with development opportunities that will strengthen the combined company as a leader for EB and other rare conditions where there are limited options for affected patients.
“We are truly excited about the future of the new company and the benefits we can bring to patients.”
For more pharma acquisition news like Castle Creek acquisition of Fibrocell, keep following Pharma News Daily.